Age-Related Macular Degeneration: Competitive Landscape to 2026

Table of Contents
1. Preface 2
1.1 Table of Contents 2
1.2 Abbreviations 3
1.3 Related Reports 5
2. Executive Summary 6
2.2 Key Findings 7
2.2 Key Events 8
3. Introduction 9
3.1 Report Scope 10
3.2 Disease Overview and Epidemiology 12
4. Pipeline Assessment 16
4.1 Pipeline Overview 17
4.2 Pipeline Breakdown by Region/Country 19
4.3 Pipeline Breakdown by Molecule Type and Target 20
4.4 Drug Review Designations 21
4.5 Products in Clinical Development 22
5. Clinical Trial Assessment 24
5.1 Clinical Trials Overview 25
5.2 Top Sponsors of Clinical Trials in AMD 26
5.3 Trial Breakdown by Region 28
5.4 Therapy Area Perspective 29
5.5 Enrollment Analytics 30
6 Commercial Assessment 33
6.1 Leading Marketed Products 34
6.2 Current & Future Players 35
7. Competitive Landscape Analysis (2016-2026) 36
7.1 Events Classification Overview 37
7.2 US 38
7.3 5EU 39
7.4 Japan 40
7.5 China 41
8 Appendix 42
8.1 Sources 43
8.2 Methodology 44
8.3 Key Events Included in the Analysis 45
8.4 About the Authors 46
8.5 About GlobalData 49
8.6 Disclaimer 50